Can antibodies keep HIV in check without daily pills?

NCT ID NCT06031272

Ongoing Disease control Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two lab-made antibodies can safely control HIV in people who stop their regular antiretroviral therapy for a short time. Thirty-two adults in Sub-Saharan Africa who are currently on HIV treatment will receive either the antibodies or a placebo. The goal is to see if the antibodies can keep the virus suppressed and are safe to use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Aurum Institute Klerksdorp CRS (30325)

Klerksdorp, North West, South Africa
Blantyre CRS (30301)

Blantyre, Malawi
CAPRISA eThekwini CRS (31422)

Durban, KwaZulu-Natal, 4011, South Africa
Gaborone CRS (12701)

Molepolole, Botswana
Groote Schuur HIV CRS (31708)

Cape Town, Western Cape, 7925, South Africa
Lilongwe Malawi CRS (12001)

Lilongwe, Malawi
Rustenburg CRS (31684)

Rustenburg, North West, 0300, South Africa
Soweto HVTN CRS (30351)

Soweto, Gauteng, 1862, South Africa
Ward 21 CRS (31966)

Johannesburg, Gauteng, 2001, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.